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SUMMARY 
Background:  Dyslipidaemia is one of the cardiovascular risk factors responsible for cardiovascular disease and  
rapid progression of chronic kidney disease (CKD) to end stage renal disease. Early detection and management of 
dyslipidaemia will reduce cardiovascular burden and retard progression of CKD.  
Aims: To determine the prevalence and pattern of dyslipidaemia in pre-dialysis CKD patients in a tertiary hospital 
in southern Nigeria. 
Methods: This was a case-control study that involved 105 consecutive pre-dialysis CKD patients recruited over two 
years and 105 age and sex matched control subjects. Data obtained from participants included demographics, body 
mass index, and aetiology of CKD. Blood sampling was done for the determination of creatinine and fasting serum 
lipids. P values < 0.05 were taken as significant. 
Results: The mean age of the CKD  and control subjects were 46.98±16.81 and 47.57±15.97 years respectively with 
a male:female ratio of 1.7:1. The median atherogenic index of plasma (AIP), low density lipoprotein-cholesterol and 
triglyceride (TG) were significantly higher in the CKD patients while mean high density lipoprotein-cholesterol 
(HDL-C) was significantly lower in the CKD patients (p=<0.001). The overall prevalence of dyslipidaemia in the 
CKD patients was 60% which was significantly higher than 39% in the control (p=0.002). The prevalence of high 
AIP, elevated TG and reduced HDL-C increased with worsening renal function. Dyslipidaemia was commoner in 
female CKD patients (p=0.02) and those who were ≥ 45years (p=0.94).  
Conclusion: Dyslipidaemia is common in pre-dialysis CKD especially in female and older patients. Some lipid ab-
normalities increased with worsening kidney function.  
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INTRODUCTION 
Cardiovascular disease is the leading cause of hospitali-
zation and mortality in patients with chronic kidney 
disease.1 The process of cardiovascular disease most 
likely started in early stages of CKD considering its 
severity at commencement of renal replacement therapy 
(RRT).2 Dyslipidaemia is one of the recognized tradi-
tional cardiovascular risk factors in the general popula-
tion as well as CKD patients.3,4  This cardiovascular risk 
factor occurs commonly in  patients with CKD. 5-7  
 
Dyslipidaemia is associated with rapid decline in renal 
function and commencement of RRT in CKD pa-
tients.8,9 The precise mechanism is unknown, but it has 
been postulated that mesangial cells bind and take up 
oxidized LDL which then causes injury to mesangial, 
epithelial and endothelial cells by favouring  recruit-
ment of inflammatory cells such as macrophages which 
release cytokines, chemokines and growth factors.10,11  
This subsequently leads to glomerulosclerosis.10 Hyper-
cholesterolaemia and hypertriglyceridaemia also cause 
podocyte injury and mesangial sclerosis, subsequently 
leading to glomerulosclerosis.  
 
Dyslipidaemia in CKD patients is characterized by ele-
vated triglyceride (TG), elevated total cholesterol (TC),  
high density lipoprotein cholesterol (LDL-C) and re-
duced high density lipoprotein cholesterol (HDL-C).5-7  
However, total cholesterol may be normal or reduced 
especially in the presence of malnutrition. The pattern 
of dyslipidaemia seen in CKD patients is highly athero-
genic and is associated with development of atheroscle-
rotic cardiovascular disease and all cause mortality.12 
 
Dyslipidaemia is a modifiable cardiovascular risk fac-
tor, hence early diagnosis and management with both 
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will reduce cardiovascular disease risk and progression 
to end stage renal disease (ESRD). Treatment of 
dyslipidaemia using statins has been reported to reduce 
the rate of decline in glomerular filtration rate (GFR) in 
CKD patients.13  
 
We set out to determine the prevalence and pattern of 
dyslipidaemia in relation to age, gender and severity of 
CKD among pre-dialysis CKD patients attending a 




The Renal unit, Department of Internal Medicine of 
University of Benin Teaching Hospital receives referral 
from within and outside the state of location.  Renal 
clinic is run thrice weekly on consultant out-patients 
basis where an average of 10 newly diagnosed CKD 
patients are seen in the unit monthly.  
 
Study Design 
This was a case control study spanning over a 2-year 
period (September 2011 to August 2013) that involved 
105 consecutive pre-dialysis CKD patients that fulfilled 
criteria for the study and 105 age and sex matched con-
trols.  Sample size was derived using the Fleiss formula 
for case-control study using the following information: 
14  
 
Confidence interval = 95%, power of study = 80%, ratio 
of cases to control of 1:1, percentage of control ex-
posed:  8.7% 15 and percentage of cases exposed: 26% 5 
(both were gotten from previous studies on dyslipidae-
mia in subjects with normal renal function and CKD 
respectively). This formula gave a minimum sample 
size of 75 for cases and 75 for control.  
 
Inclusion criteria for CKD subjects were: adults aged ≥ 
18 years, patients with CKD stages 1-5 yet to com-
mence dialysis. CKD patients who were pregnant, al-
ready on dialysis, those who had renal transplant and 
those on dietary restriction (lipid lowering diet), lipid 
lowering medications, steroids or immunosuppressant 
were excluded from the study. Inclusion criteria for con-
trol subjects were adults aged ≥18 years who were not 
hypertensive nor diabetic with normal renal function, 
females who were not pregnant and  not on steroids, 
immunosuppressant or lipid lowering medications.  
 
 
Demographic information including age and sex of par-
ticipants were obtained. Patients were interviewed, ex-
amined and aetiologies of renal disease were deter-
mined. Weight was measured using a weighing scale 
made by U-MEC (model 98114) with subjects wearing 
light clothing.  
 
The weighing scale was calibrated with known weights 
at the beginning of each clinic session and it was en-
sured that the scale was zeroed before measurements 
were taken in order to ensure accuracy of measure-
ments.  Height was   measured   using   a   stadiometer 
to the nearest centimeter with subjects neither wearing 
shoes nor head gear. Body mass index (kg/m2) was cal-
culated using the formula Weight (kg)/Height2 (m) 2. 
 
About 10mls of fasting venous blood was obtained from 
patients to perform biochemical tests which included 
serum creatinine and fasting serum lipids. Total serum 
cholesterol and triglycerides were determined by enzy-
matic estimation,16  while HDL-C was determined by 
precipitation.17 LDL-C was estimated using Friedwald 
formula.18 Glomerular filtration rate  was estimated us-
ing the Cockcroft Gault formula which has been previ-
ously validated in Nigerian subjects.19 
 
Definition of variables 
Obesity was defined as BMI > 29.9kg/m2.20  CKD stage 
1 (GFR  ≥ 90 mls/min with evidence of kidney dam-
age), stage 2 (GFR  60-89 mls/min  with evidence of 
kidney damage), stage 3 (GFR = 30-59 mls/min with or 
without evidence of kidney damage), stage 4 (GFR =15-
29 mls/ min with or without evidence of kidney dam-
age) and stage 5 (GFR < 15mls/min with or without 
evidence of kidney damage). 21 Dyslipidaemia was de-
fined as any or a combination of the following: TC > 
200 mg/dl, HDL-C < 50 mg/dl in females and < 40 
mg/dl in males, LDL-C > 135 mg/dl and TG  > 
150mg/dl.22  Atherogenic index of plasma (AIP) > 0.24 
was regarded as high cardiovascular risk.23 
 
Ethical approval was obtained from the hospital ethics 
committee on research and informed consent was ob-
tained from participants. 
 
Data Analysis 
Data generated were analyzed using the statistical pack-
age for social sciences (SPSS) version 17.0. Results 
were presented in tabular forms. Univariate analysis was 
used in description of demographic characteristics of the 
study population. Continuous variables were presented 
as mean and standard deviation for unskewed data  and 
median, interquartile range for skewed data.  
Student t-test was used to compare mean values of the 
sub-groups for those with unskewed data while Mann 
Whitney U test was used to compare skewed data. Dis-
crete variables were presented as frequency and per-
centages. Chi-square test was used to determine the sig-




                                                                                                                                                                               
www.ghanamedj.org  Volume 50 Number 1 March 2016 46 
bles while chi-square with trend was used where the 




This study involved 105 CKD patients and 105 age and 
sex matched control subjects. Each group comprised of 
66 males and 39 females.  About 48% of the CKD sub-
jects were below 45 years. Chronic glomerulonephritis, 
hypertension and diabetes mellitus were the major aeti-
ology of renal disease, accounting for 33.3%, 32.4% and 
29.5% respectively. Most of these patients were in CKD 
stages 3 and 4, accounting   for   68.6% of the patients.  
(Table 1) 
 
Table 1 Characteristics of study subjects 




Parameter     n (%)     n (%) 
Gender   
Male 66 (62.9) 66 (62.9) 
Female 39 (37.1) 39 (37.1) 
Age   
<45years 47 (47.8) 47 (47.8) 
≥45 years  58 (52.2) 58 (52.2) 
Diagnosis   
Chronic glo-
merulonephritis 
35 (33.3)  
Hypertensive 
nephropathy 
34 (32.4)  
Diabetic 
nephropathy 
31 (29.5)  
Others 
 
  5 (4.8)  
CKD stages   
1 7 (6.7)  
2 22 (21.0)  
3 46 (43.8)  
4 26 (24.8)  
5 4   (3.8)  
 
Table 2 shows a comparison of characteristics of the 
CKD and control groups. The mean age of the CKD and 
the control groups were 46.98±16.81 years and 
47.57±15.97 years respectively with no significant dif-
ference (p=0.794). There was no significant difference 
in the mean serum TC between the CKD and control 
groups.  
 
The mean HDL-C and BMI were significantly lower in 
the CKD patients with p values of <0.001 and 0.02 re-
spectively.  The median serum creatinine, TG, LDL-C 
and AIP were significantly higher in the CKD group 
compared with the control group with p values of 
<0.001. 
 
Table 2: Comparison of parameters between the CKD 
and control groups   




 P value 
Age (years) 46.98±16.81 47.57±15.97 0.794 
BMI (kg/m2) 24.49±4.18 26.03±5.00 0.02 
Serum TC (mg/dl) 182.34±45.01 178.95±53.91 0.621 
Serum TG† (mg/dl) 105(60) 72(59) <0.001 
Serum HDL-C(mg/dl) 53.60± 20.91 74.51±24.23 <0.001 
Serum LDL-C†(mg/dl) 101(214) 85(70) <0.001 
Atherogenic index of 
Plasma† 
0.34(0.32) 0.01(0.48)  <0.001 
Serum creati-
nine†(mg/dl) 
2.90(2.30) 0.70(0.40)  <0.001 
† Skewed data expressed in Median(IQR) and Man Whitney U test 
used. IQR (Interquartile range),TC(total cholesterol),  
 TG(triglyceride), LDL-C (low density lipoprotein-cholesterol), HDL-
C (high density lipoprotein-cholesterol) 
 
The prevalence of lipid abnormalities present in CKD 
versus control subjects were; elevated TC (29.5% vs 
29.5%), elevated TG (19.0% vs 13.3%), elevated LDL-
C (16.2% vs 15.2%), low HDL-C (30.5% vs 7.6%), 
high AIP  (64.8% vs 33.8%). The prevalence of reduced 
serum HDL-C, high AIP and dyslipidaemia were signif-
icantly higher in the CKD groups compared to the con-
trol with p values of <0.001, <0.001 and 0.002 respec-
tively. There was no significant difference between the 
prevalence of elevated serum TC, TG and LDL-C in 
both groups. The overall prevalence of dyslipidaemia 
was 60.0% in the CKD patients which was significantly 
higher than 39% present in the control subjects. (Table 
3) 
 
Table 3 Comparison of Lipid abnormality between the 
CKD and control group 
LIPID ABNOR-
MALITY 
CKD group  
n(%) 
Control group  
n(%) 
P value 
Elevated TC 31(29.5) 31(29.5) 1.000 
Elevated TG 20(19.0) 14(13.3) 0.261 
Elevated LDL-C 17(16.2) 16(15.2) 0.850 
Reduced HDL-C 32(30.5) 8(7.6) <0.001 
High AIP 68(64.8) 25(33.8) <0.001 
Dyslipidaemia 63(60.0) 41(39.0) 0.002 
 
 
The prevalence of elevated serum TG, reduced serum 
HDL-C and high AIP increased significantly across 
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There was no significant increase in prevalence of ele-
vated serum TC, elevated serum LDL-C and dyslipi-
daemia across the CKD stages.(Table 4) 
  
Table 4 Prevalence of Lipid abnormalities across the CKD stages 
Parameter CKD stage 1 
n (%) 
CKD stage 2         
n (%) 
CKD stage 3 
n (%) 
CKD stage 4 
     n (%) 
CKD stage 5  
     n (%) 
P value 
Elevated TC 3(42.9%) 9(40.9%) 10(21.7%) 7(26.9%) 2(50%) 0.37 
Elevated TG 0(0%) 3(13.6%) 8(17.4%) 4(26.9%) 2(50%) 0.02 
Elevated LDL-C 2(28.6%) 3(13.6%) 6(13%) 5(19.2%) 1(25%) 0.82 
Reduced HDL-C 2(28.6%) 2(9.1%) 16(34.8%) 10(38.5%) 2(50%) 0.04 
High AI 3(42.9%) 12(54.5%) 30(65.2%) 20(76.9%) 3(75%) 0.03 
Dyslipidaemia 5(71.4%) 12(54.5%) 27(58.7%) 15(57.7%) 4(100%) 0.72 
 
Table 5 Association between dyslipidaemia, gender, 





Absent   
n(%) 
P value 
Male 34(51.5) 32(48.5) 0.02 
Female 29(74.4) 10 (25.6)  
<45years 19(40.4) 28(59.6) 0.94 
≥45years 35(60.3) 23(39.7)  
Non-obese 57(61.3) 36(38.7) 0.45 
Obese 6(50.0) 6(50.0)  
 
The prevalence of dyslipidaemia was 74.4 % in female 
CKD patients and this was significantly higher than 
51.5% present in male CKD patients (p=0.02).  Dyslipi-
daemia was commoner in CKD patients who were 45 
years and above although this was not statistically sig-
nificant (p=0.94). There was also no significant associa-
tion between obesity and dyslipidaemia in the CKD 
patients. (Table 5) 
 
DISCUSSION 
The mean age of the CKD patients was 46.98±16.81 
years which is similar to previous reports in Nigeria.5,24  
This buttresses the fact that CKD affects the economi-
cally productive age group in Nigeria. Majority of the 
CKD patients were in stages 3 and 4 and this may be 
explained by poor health seeking habits and late presen-
tation of Nigerians patients. 
 
The median serum TG, LDL-C were significantly high-
er while mean serum HDL-C was lower in the CKD 
group compared to the control in this study. This pattern 
of dyslipidaemia is similar to reports from previous 
studies from other parts of Nigeria.6,7  
 
There was no significant difference between mean se-
rum TC in both groups  which  is also similar to the 
reports by Agaba et al.25  
 
The overall prevalence of dyslipidaemia in the CKD 
patients in this study was 60% and was commoner in 
those who were 45 years and above. Earlier studies on 
lipid profile of adult Nigerian CKD patients assessed 
prevalence of individual lipid abnormality, but not over-
all prevalence of dyslipidaemia in the studied popula-
tion.5-7 This prevalence is however high compared to  
the overall prevalence of 45% reported  in a paediatric 
CKD population.28 The lower prevalence in the latter 
study may be  explained by the conservative cut off 
used in the definition of dyslipidaemia and also by the 
fact that it was conducted in a paediatric age group.  
 
Dyslipidaemia was significantly higher in female CKD 
patients compared to the male subjects.   The higher 
prevalence of dyslipidaemia in female CKD patients 
may be explained by the higher cut off of less than 
50mg/dl used to diagnosed low HDL compared to a 
lower value of less than 40mg/dl used in males. Also, 
oestrogen which is known to be protective against 
dyslipidaemia by increasing the levels of HDL-C in 
premenopausal females is usually low in females CKD 
patients.29 
 
There was association between dyslipidaemia and sever-
ity of CKD unlike previous reports.6,7  This study 
showed significant increase in the prevalence of reduced 
HDL-C and elevated TG with worsening GFR, hence 
early evaluation and management of dyslipidaemia 
should be advocated in these patients in order to retard 
progression of CKD to ESRD and prevent development 
of cardiovascular disease. 
 
The AIP has been reported to have higher sensitivity 
compared to other ratios in predicting cardiovascular 
events in patients.30   
 
It is the best determinant of fractional esterification rate 
of HDL-C and thus, a better predictor of cardiovascular 
risk than previously used lipid parameters.31 The preva-
lence of CKD patients with high AIP was 64.8% and 
this was significantly higher than 33.8% found in the 
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This is the first study (to the best of our knowledge)  
that  assessed AIP across CKD stages in Nigeria. There 
was also significant increase in AIP in the CKD patients 
with worsening renal function. It could also be inferred 
that that there is increasing susceptibility of CKD pa-
tients to myocardial infarction with worsening renal 
function since AIP strongly predicts myocardial infarc-
tion.32 The prevalence of high AIP was higher than the 
individual lipid abnormality or overall dyslipidaemia. 
This underscores the need to evaluate CKD patients for 
atherogenic risk by using ratios from the different lipid 
components instead of considering each component  in 
isolation. 
 
The use of statins has been found to reduce cardiovascu-
lar risk and retards CKD progression.13,33 Schieffer et al 
also reported that weight reduction significantly reduce 
atherogenic risk factors such as blood pressure and vari-
ous lipid components,34  hence regular exercise and life-
style modification aimed at weight loss will also com-
plement the effect of  lipid lowering medications. 
 
In conclusion, dyslipidaemia is a common cardiovascu-
lar risk factor in CKD especially in females and older 
CKD patients. Some lipid abnormalities such as reduced 
HDL-C, elevated TG and atherogenic risk tend to in-
crease with worsening renal function.  
 
We recommend early evaluation of CKD patients for 
dyslipidaemia and cardiovascular risk using ratio of 
lipid components at all stages with the aim of manage-
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